S021 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
DESCRIPTION
This session will provide an overview of national recommendations for management of cutaneous melanoma, utilizing current NCCN and AAD clinical practice guidelines. Based on the available, worldwide evidence: faculty speakers will address: appropriate biopsy techniques, pathology assessment (including AJCC 8th edition staging), molecular/gene expression profiling (for biopsy, pathologic assessment and prognosis), sentinel lymph node biopsy (including risk prediction tools), surgery (including Mohs micrographic surgery and staged excision with permanent sections), topical imiquimod for melanoma in situ/lentigo maligna type, surveillance imaging, and adjuvant therapy for resected stage II (primary) and stage III (node-positive) melanoma.
LEARNING OBJECTIVES
Apply current AAD and NCCN cutaneous melanoma guidelines to clinical practice, including biopsy techniques, pathology evaluation, baseline/surveillance studies, molecular testing and surgical management.
Recognize potential limitations and benefits of diagnostic and prognostic molecular testing for clinical-decision making, including initial biopsy, pathology diagnosis, SLNB risk prediction and prognosis.
Describe the role of adjuvant therapy for resected stage II and stage III melanoma, including potential risks and benefits.
SCHEDULE
1:00 PM
Introduction
Susan M. Swetter, MD, FAAD
1:05 PM
Pathology Reporting & AJCC Staging
Michael Tetzlaff, MD, PhD
1:25 PM
Tools for Bedside Diagnosis of Melanoma
Caroline C. Kim, MD, FAAD
1:45 PM
Biopsy Techniques and Primary Surgery
Susan M. Swetter, MD, FAAD
2:05 PM
Mohs Micrographic Surgery/Staged Excision
Wesley Yu, MD, FAAD
2:25 PM
Alternative Therapies for Melanoma in situ/Lentigo Maligna
Kelly C Nelson, MD, FAAD
2:45 PM
Prognostic Gene Expression Profiling and SLNB Risk Prediction
Douglas Grossman, MD, PhD, FAAD
3:05 PM
Sentinel Lymph Node Biopsy Updates
Christopher K. Bichakjian, MD, FAAD
3:25 PM
Adjuvant Therapies for Primary/Metastatic Melanoma
Hensin Tsao, MD, PhD, FAAD
3:45 PM
Panel Discussion
DIRECTOR
Susan M. Swetter, MD, FAAD
SPEAKERS
Christopher K. Bichakjian, MD, FAAD
Douglas Grossman, MD, PhD, FAAD
Caroline C. Kim, MD, FAAD
Kelly C Nelson, MD, FAAD
Michael Tetzlaff, MD, PhD
Hensin Tsao, MD, PhD, FAAD
Wesley Yu, MD, FAAD
HANDOUTS
DISCLOSURES
Christopher K. Bichakjian, MD, FAAD
No financial relationships exist with ineligible companies.
Douglas Grossman, MD, PhD, FAAD
DermTech Inc. – Investigator(Fees); OrLucent, Inc. – Advisory Board(Honoraria), Investigator(Fees); Skin Analytics – Investigator(Fees);
Caroline C. Kim, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.
Susan M. Swetter, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Tetzlaff, MD, PhD
No financial relationships exist with ineligible companies.
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); Oncobay Clinical – Consultant (1099 relationship)(Fees); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);
Wesley Yu, MD, FAAD
Castle Biosciences – Advisory Board(Honoraria); SkylineDx B.V. – Investigator(Grants/Research Funding);